COMMUNIQUÉS West-GlobeNewswire
-
New review prioritizes maternal mental health during pregnancy
12/08/2026 -
Interra Health Named on the 2026 Inc. 5000 List of America’s Fastest-Growing Private Companies
12/08/2026 -
Dr. Wallace Brucker Offers Galleri Multi-Cancer Early Detection Testing in Las Vegas as Part of Proactive Longevity Care
12/08/2026 -
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
12/08/2026 -
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
12/08/2026 -
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
12/08/2026 -
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
12/08/2026 -
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
12/08/2026 -
ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments
12/08/2026 -
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
12/08/2026 -
Reflect Scientific Reports More Than $1.4 Million in Freezer-System Sales to Biopharmaceutical Customers
12/08/2026 -
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
12/08/2026 -
Solana Company to Release Second Quarter 2026 Operating Results on August 14, 2026
12/08/2026 -
MUHC Foundation President and CEO Marie-Hélène Laramée appointed to Women’s Health Collective Canada Board of Directors
12/08/2026 -
Marie-Hélène Laramée, présidente-directrice générale de la Fondation du CUSM, nommée au conseil d’administration de l’Association canadienne pour l’équité en santé des femmes
12/08/2026 -
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
12/08/2026 -
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
12/08/2026 -
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
12/08/2026 -
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
12/08/2026
Pages